Kineta (NASDAQ:KA) Stock Price Down 7.4%

Kineta, Inc. (NASDAQ:KA)’s share price fell 7.4% during mid-day trading on Wednesday . The company traded as low as $0.60 and last traded at $0.62. 172,659 shares were traded during trading, a decline of 42% from the average session volume of 298,369 shares. The stock had previously closed at $0.67.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and set a $8.00 target price on shares of Kineta in a report on Thursday, January 18th.

Kineta Stock Performance

The stock’s 50-day simple moving average is $0.98 and its 200 day simple moving average is $2.56. The company has a debt-to-equity ratio of 0.05, a quick ratio of 0.85 and a current ratio of 0.85. The company has a market capitalization of $6.80 million, a PE ratio of -0.45 and a beta of 0.52.

Kineta (NASDAQ:KA) last announced its quarterly earnings data on Thursday, March 21st. The company reported ($0.19) EPS for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.10. As a group, research analysts expect that Kineta, Inc. will post -1.41 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Kineta stock. Manchester Capital Management LLC acquired a new position in shares of Kineta, Inc. (NASDAQ:KA) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 10,216 shares of the company’s stock, valued at approximately $35,000. Manchester Capital Management LLC owned about 0.10% of Kineta as of its most recent filing with the SEC. 30.32% of the stock is currently owned by hedge funds and other institutional investors.

Kineta Company Profile

Kineta, Inc is a clinical-stage biotechnology company with a focus on developing immunotherapies that transform patients' lives. It focuses on developing potentially differentiated immunotherapies that address the challenges with current cancer therapy. The company's immuno-oncology pipeline includes KVA12123, a VISTA blocking immunotherapy in development as a twice weekly monoclonal antibody (mAb) infusion drug.